An observational study in Coronary Artery Disease and Angioplasty, Balloon, sponsored by Seung-Jung Park. Recruiting at 9 sites in South Korea. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2025-12-29.
Sponsored by Seung-Jung Park · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 59 studies in Coronary Artery Disease by Seung-Jung Park — 11 open to participants now, 13 under way, none of them phase 3. Coronary Artery Disease · Seung-Jung Park.
Among the 59 studies in Coronary Artery Disease by Seung-Jung Park, this one is the 18th largest by planned enrollment of the 30 observational ones that give a count, is one of 7 that started in 2014, is one of 30 observational ones, reaches primary completion later than 2 of the 12 other live ones, and was the 40th registered.
4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.
Browse Coronary Artery Disease studies →11 of the 59 studies in Coronary Artery Disease by Seung-Jung Park are open now, in 8 countries. Recruiting first, the newest first:
Seung-Jung Park · Sites in Korea, Republic of
Ages 19+
Seung-Jung Park · Sites in Hong Kong, India, Japan and 2 more countries
Ages 20+
Seung-Jung Park · Sites in Korea, Republic of
Ages 19+
Seung-Jung Park · Sites in Korea, Republic of
Ages 19+
Seung-Jung Park · Sites in Korea, Republic of
Ages 19+
By country, each count listing its studies:
Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
59 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 7 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,500 is above the median of 323 across 1,690 observational studies indexed under Coronary Artery Disease.
Median enrollment 500 across the 29 interventional studies, 2,000 across the 30 observational. Of the 46 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Seung-Jung Park is the lead sponsor of 82 studies on the registry; 13 are open to participants now.
3 of the studies in Coronary Artery Disease by Seung-Jung Park that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02792075Seung-Jung ParkPrognosis of Coronary Stenosis Based on Intracoronary Imaging; A Multicenter, Prospective Observational Study | 2026-12 |
| NCT02038660Seung-Jung ParkDrug-Eluting Balloon Registry in Routine Clinical Practice | 2026-12-31 |
| NCT05829889Seung-Jung ParkFractional Flow Reserve Versus Angiography for Treatment-Decision and Evaluation of Significant Left MAIN Coronary Artery Disease | 2027-06 |
Add all 3 to your calendar (.ics) → With an account.
Among the 59 studies in Coronary Artery Disease by Seung-Jung Park, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate long-term effectiveness and safety of patients with coronary disease treated with drug eluting balloon in real world practice.
Patients treated with balloon angioplasty
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Device: Balloon angioplasty
Composite Event
Death, Non-fatal myocardial infarction, Target vessel revascularization
Time frame: 1year
All cause death
Time frame: 5year
Cardiac death
Time frame: 5year
Myocardial infarction
Time frame: 5year
Composite event
Death or myocardial infarction
Time frame: 5year
Composite event
Cardiac death or myocardial infarction
Time frame: 5year
Target vessel revascularization
Time frame: 5year
Target lesion revascularization
Time frame: 5year
Stent thrombosis
Classification of stent thrombosis according to Academic Research Consortium criteria
Time frame: 5year
Stroke
Time frame: 5year
Procedural Success
Defined as less than 30% residual stenosis at the completion of procedure without death or Q wave myocardial infarction or urgent revascularization. Participants will be followed for the duration of hospital stay, an expected average of 3days.
Time frame: 3day
Not enrolling at this site.
Not enrolling at this site.
Plan to share: No — This is not a publicly funded trial.
No publications or documents are linked to this record.
Started Jan 2014 (actual). Primary completion is estimated for Dec 2026, 155 months after the start.
Of 637 non-industry observational studies under Coronary Artery Disease, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 122. This study's planned 155 months is above that.
Counting every sponsor, half of 762 studies reached it within 41 months; a quarter within 21 and three quarters within 87.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Seung-Jung Park